Streetbeat News

BPTS

Biophytis

https://www.biophytis.com/

CEO

Stanislas Veillet

Employees

14

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

biophytis is a biotech company developping therapeutics for aging diseases. it that has been created in 2006 as a spin-off of université pierre et marie curie (paris). biophytis has developped a portfolio of drug candidates at clinical stage for the treatment of sarcopenic obesity (bio101, bio103) and dry age-related macular degeneration (bio201).

Open

8.24

Mkt cap

2.6M

Volume

18K

High

8.96

P/E Ratio

-0.06

52-wk high

168.80

Low

8.05

Div yield

N/A

52-wk low

8.05

Trading for BPTS was halted at 7:50:00 p.m. ET due to pending news. The halt is a temporary measure until the news affecting the company is released.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:50 pm

Biophytis shares are trading lower following the announcement of a change in the ratio of its American Depositary Shares (ADS) from 100 to 4,000.

Portfolio Pulse from Benzinga Newsdesk

April 19, 2024 | 3:28 pm

Biophytis SA announced a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares, moving from one ADS representing 100 shares to one ADS representing 4,000 shares, effective April 23, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 19, 2024 | 6:48 am

Biophytis shares are trading higher following the announcement of a new Scientific Advisory Board to support its phase 2 OBA clinical study in obesity.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 7:27 pm

Biophytis SA, a clinical-stage biotech company, announced plans to file an IND with the FDA for a Phase 2 clinical study in obesity, supported by a new Scientific Advisory Board. The study will focus on developing BIO101 in combination with GLP1-RA. The advisory board includes global medical experts in obesity.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 7:01 am

Medical Properties Trust, Inc. (MPW) shares surged 13.1% in pre-market trading after selling its majority interest in Utah Hospitals. Other stocks also showed significant movement in pre-market trading, with notable gainers including Allarity Therapeutics, Inc. (ALLR), Longeveron Inc. (LGVN), and Piedmont Lithium Inc. (PLL), among others. Conversely, several stocks experienced declines, such as AudioEye, Inc. (AEYE), NextPlat Corp (NXPL), and Polestar Automotive Holding Uk Plc (PSNY), driven by various company-specific news and analyst actions.

Portfolio Pulse from Avi Kapoor

April 15, 2024 | 9:45 am

In Wednesday's after-market session, health care stocks saw significant movement. Rallybio, Vera Therapeutics, and Biophytis were among the top gainers, with Rallybio leading at a 31.9% increase. On the downside, CytomX Therapeutics, Orgenesis, and OneMedNet were the major losers, with CytomX Therapeutics experiencing a 7.2% drop. These movements reflect the volatile nature of health care stocks in the market.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 8:31 pm

Ascent Solar Technologies, Inc. (ASTI) shares fell by 50% after announcing a $6 million public offering at $0.14 per share. Other stocks experienced significant movements, with Marin Software (MRIN) and Adial Pharmaceuticals (ADIL) among the top gainers, while VIA optronics (VIAO) and Velo3D, Inc. (VLD) led the losers.

Portfolio Pulse from Avi Kapoor

April 10, 2024 | 6:07 pm

In Wednesday's intraday session, several healthcare stocks experienced significant movements. Adial Pharmaceuticals led the gainers with a 61.6% increase, while Acorda Therapeutics headed the losers with a 20.4% decrease. Other notable movers included Jaguar Health, Orgenesis, BioSig Technologies, and Telomir Pharmaceuticals on the gainers' side, and Kineta, DocGo, Biophytis, Yield10 Bioscience, and Eyenovia among the losers.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 4:31 pm

PriceSmart, Inc. (NASDAQ:PSMT) shares rose by approximately 5% in pre-market trading after reporting Q2 earnings of $1.31 per share, surpassing estimates of $1.25 per share, with sales of $1.29 billion against expected $1.28 billion. Other stocks also showed significant movement in pre-market trading, with notable gainers including Marin Software, iCoreConnect, and Nano Labs, and losers such as FutureFuel Corp, Destiny Tech100, and PainReform Ltd.

Portfolio Pulse from Avi Kapoor

April 10, 2024 | 12:12 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.